These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27096594)

  • 1. Ibrutinib for Chronic Lymphocytic Leukemia.
    Burger JA; Styles L; Kipps TJ
    N Engl J Med; 2016 Apr; 374(16):1594-5. PubMed ID: 27096594
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib for Chronic Lymphocytic Leukemia.
    Ruchlemer R; Ben Ami R; Lachish T
    N Engl J Med; 2016 Apr; 374(16):1593-4. PubMed ID: 27096597
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib for Chronic Lymphocytic Leukemia.
    Rigolin GM; Cavazzini F; Cuneo A
    N Engl J Med; 2016 Apr; 374(16):1593. PubMed ID: 27096596
    [No Abstract]   [Full Text] [Related]  

  • 4. Ibrutinib for Chronic Lymphocytic Leukemia.
    Sharman JP; Mato AR; Keating MJ
    N Engl J Med; 2016 Apr; 374(16):1592-3. PubMed ID: 27096595
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia.
    Aronson FR
    Ann Intern Med; 2016 Apr; 164(8):JC44. PubMed ID: 27089094
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    Burger JA; Tedeschi A; Barr PM; Robak T; Owen C; Ghia P; Bairey O; Hillmen P; Bartlett NL; Li J; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre S; Quach H; Gaidano G; Maslyak Z; Stevens DA; Janssens A; Offner F; Mayer J; O'Dwyer M; Hellmann A; Schuh A; Siddiqi T; Polliack A; Tam CS; Suri D; Cheng M; Clow F; Styles L; James DF; Kipps TJ;
    N Engl J Med; 2015 Dec; 373(25):2425-37. PubMed ID: 26639149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Sinha R; Redekop WK
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival adjusting for crossover: phase 3 study of ibrutinib
    Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
    Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
    [No Abstract]   [Full Text] [Related]  

  • 9. Ibrutinib in relapsed chronic lymphocytic leukemia.
    Neffendorf JE; Gout I; Hildebrand GD
    N Engl J Med; 2013 Sep; 369(13):1277. PubMed ID: 24066759
    [No Abstract]   [Full Text] [Related]  

  • 10. Ibrutinib in relapsed chronic lymphocytic leukemia.
    Byrd JC; O'Brien S; James DF
    N Engl J Med; 2013 Sep; 369(13):1278-9. PubMed ID: 24066758
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib in relapsed chronic lymphocytic leukemia.
    Rushworth SA; MacEwan DJ; Bowles KM
    N Engl J Med; 2013 Sep; 369(13):1277-8. PubMed ID: 24066760
    [No Abstract]   [Full Text] [Related]  

  • 12. Life after ibrutinib? A new unmet need in CLL.
    Pinilla-Ibarz J; Chavez JC
    Blood; 2015 Mar; 125(13):2013-4. PubMed ID: 25814485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.
    Molica S
    Expert Rev Hematol; 2013 Oct; 6(5):543-6. PubMed ID: 24083545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib, ibrutinib show benefits in CLL.
    Cancer Discov; 2014 Apr; 4(4):382. PubMed ID: 24706642
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of ibrutinib in chronic lymphocytic leukemia.
    Damon LE
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
    [No Abstract]   [Full Text] [Related]  

  • 16. [Ibrutinib - new tool in hematologist hand, new challenges for internist].
    Majcherek M; Dworacka M; Dworacki G
    Wiad Lek; 2017; 70(1):92-95. PubMed ID: 28343201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
    Montillo M; O'Brien S; Tedeschi A; Byrd JC; Dearden C; Gill D; Brown JR; Barrientos JC; Mulligan SP; Furman RR; Cymbalista F; Plascencia C; Chang S; Hsu E; James DF; Hillmen P
    Blood Cancer J; 2017 Feb; 7(2):e524. PubMed ID: 28157216
    [No Abstract]   [Full Text] [Related]  

  • 18. Ibrutinib for Chronic Lymphocytic Leukemia with
    Ahn IE; Tian X; Wiestner A
    N Engl J Med; 2020 Jul; 383(5):498-500. PubMed ID: 32726539
    [No Abstract]   [Full Text] [Related]  

  • 19. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Goldschmidt N; Rund D
    Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
    [No Abstract]   [Full Text] [Related]  

  • 20. Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
    Tucker DL; Mihailescu L; Riordan R; Rule S
    Br J Haematol; 2017 Jul; 178(1):153-155. PubMed ID: 27172457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.